Arcturus Therapeutics Ltd. (NASDAQ: ARCT) is an RNA medicines company focused on rare diseases with enabling technologies – UNA Oligomer chemistry and LUNAR® lipid-mediated delivery. Arcturus also produces its own mRNA drug substance with its own proprietary process. Arcturus’ diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. LUNAR-OTC (ARCT-810) to treat Ornithine Transcarbamylase (OTC) Deficiency is expected to reach the clinic in 1H 2020 and LUNAR-CF to treat Cystic Fibrosis (CF) in 2H 2020. Arcturus’ versatile platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. The Company's commitment to the development of novel RNA therapeutics has led to significant partnerships with Janssen, Ultragenyx, Takeda, CureVac and Synthetic Genomics.